◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Ascendis Pharma AS (ASND) EBITDA 2012–TTM

Name: Ascendis Pharma AS (ASND) ebitda history 2012-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Ascendis Pharma AS annual ebitda for fiscal 2025 was -€110 million, an increase of 62.1% from -€290 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

ASND Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
EBITDA	—	(€110M)	(€290M)	(€411M)	(€529M)	(€365M)	(€408M)	(€210M)	(€150M)	(€110M)	(€72M)	(€33M)	(€11M)	€6M	€2M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASND Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	—	€24M	€40M	(€53M)	€2M	(€44M)	(€38M)	(€71M)	(€88M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

INSM EBITDA — Insmed Inc
JAZZ EBITDA — Jazz Pharmaceuticals PLC
EXEL EBITDA — Exelixis Inc
SMMT EBITDA — Summit Therapeutics PLC
BBIO EBITDA — BridgeBio Pharma Inc
HALO EBITDA — Halozyme Therapeutics Inc

More ASND metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All ASND financial statements → Interactive ASND charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.